Publicação
Unveiling novel ERCC1–XPF complex inhibitors : bridging the gap from in silico exploration to experimental design
| datacite.subject.fos | Ciências Médicas::Ciências da Saúde | |
| datacite.subject.sdg | 03:Saúde de Qualidade | |
| dc.contributor.author | Manguinhas, Rita | |
| dc.contributor.author | Serra, Patrícia A. | |
| dc.contributor.author | Soares, Rita B. | |
| dc.contributor.author | Rosell, Rafael | |
| dc.contributor.author | Gil, Nuno | |
| dc.contributor.author | Oliveira, Nuno G. | |
| dc.contributor.author | Guedes, Rita C. | |
| dc.date.accessioned | 2026-04-27T10:37:19Z | |
| dc.date.available | 2026-04-27T10:37:19Z | |
| dc.date.issued | 2024-01 | |
| dc.description.abstract | Modifications in DNA repair pathways are recognized as prognostic markers and potential therapeutic targets in various cancers, including non-small cell lung cancer (NSCLC). Overexpression of ERCC1 correlates with poorer prognosis and response to platinum-based chemotherapy. As a result, there is a pressing need to discover new inhibitors of the ERCC1–XPF complex that can potentiate the efficacy of cisplatin in NSCLC. In this study, we developed a structure-based virtual screening strategy targeting the inhibition of ERCC1 and XPF interaction. Analysis of crystal structures and a library of small molecules known to act against the complex highlighted the pivotal role of Phe293 (ERCC1) in maintaining complex stability. This residue was chosen as the primary binding site for virtual screening. Using an optimized docking protocol, we screened compounds from various databases, ultimately identifying more than one hundred potential inhibitors. Their capability to amplify cisplatin-induced cytotoxicity was assessed in NSCLC H1299 cells, which exhibited the highest ERCC1 expression of all the cell lines tested. Of these, 22 compounds emerged as promising enhancers of cisplatin efficacy. Our results underscore the value of pinpointing crucial molecular characteristics in the pursuit of novel modulators of the ERCC1–XPF interaction, which could be combined with cisplatin to treat NSCLC more effectively. | eng |
| dc.identifier.citation | Manguinhas R, Serra PA, Soares RB, Rosell R, Gil N, Oliveira NG, Guedes RC. Unveiling Novel ERCC1–XPF Complex Inhibitors: Bridging the Gap from In Silico Exploration to Experimental Design. International Journal of Molecular Sciences. 2024; 25(2):1246. https://doi.org/10.3390/ijms25021246 | |
| dc.identifier.doi | 10.3390/ijms25021246 | |
| dc.identifier.issn | 1422-0067 | |
| dc.identifier.uri | http://hdl.handle.net/10400.26/62882 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.publisher | MDPI | |
| dc.relation.hasversion | https://doi.org/10.3390/ijms25021246 | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | DNA repair pathways | |
| dc.subject | ERCC1–XPF complex | |
| dc.subject | inhibitors | |
| dc.subject | structure-based virtual screening | |
| dc.subject | structural analysis | |
| dc.subject | cisplatin | |
| dc.subject | NSCLC | |
| dc.title | Unveiling novel ERCC1–XPF complex inhibitors : bridging the gap from in silico exploration to experimental design | eng |
| dc.type | contribution to journal | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 2 | |
| oaire.citation.startPage | 1246 | |
| oaire.citation.title | International Journal of Molecular Sciences | |
| oaire.citation.volume | 25 | |
| oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 |